Evaluation of Balamruta Rasayana as Adjuvant therapy in Chemoradiation(CRT)induced Adverse effects in Adenocarcinoma in Palliative care-A Randomised open labelled clinical Study

Dr Harish Babu H0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•1. Subjects of Either Sex age between 23yr-75yr.
•2. Subjects suffering from Adenocarcinoma of Lungs, Stomach, Oesophagus, Prostate &
•Intestine diagnosed with Biopsy.
•3.Subjects undergoing Radiation and chemotherapy for above cancer presenting with Side effects.
•4.Patients who are presenting adverse effects during/after chemo/radiation.
•5.Subject provides written informed consent and gives authorization for use and disclosure of protected health information.
•6. Subject agrees not to participate in other clinical trial.

•Patients having Adenocarcinoma in more than 3 organs.
•Patients undergoing major surgery or H/o Surgery within 3 months.
•Patients having adenocarcinoma (Primary) in oral, Breast and brain.
•Patients having secondary metastatic Adenocarcinoma in Oral, brain or brain tissue.
•Subject has any Genetic diseases(Neurofibromatosis, Haemochromatosis etc)
•Subjects SPO2 less than 80
•Subjects having Adenocarcinoma with multi organ failure
•Subjects requiring dialysis
•Subjects serum is positive for HIV-1 or HIV 2 antibody
•Serum positive for Hepatitis B Surface antigen & Hepatitis.
•Subject has any underlying or current medical condition, which, in the opinion of the
•Investigator, would interfere with the evaluation of the subject

发起方

Dr Harish Babu H